Search

Your search keyword '"M.A. Climent"' showing total 35 results

Search Constraints

Start Over You searched for: Author "M.A. Climent" Remove constraint Author: "M.A. Climent" Publisher elsevier bv Remove constraint Publisher: elsevier bv
35 results on '"M.A. Climent"'

Search Results

2. 1572P The impact of COVID-19 pandemic on Spanish genitourinary (GU) cancer patients: SOGUG-COVID-19 study

3. 666P Pembrolizumab (pembro) monotherapy as first-line therapy in advanced clear cell renal cell carcinoma (ccRCC): Results after a minimum of 41 months of follow-up from KEYNOTE-427 cohort A

4. 589P Dynamics of peripheral blood immune profiling associated with tumour progression in metastatic castration resistant prostate cancer (mCRPC)

5. 625P TMPRSS2-ERG expression and clinical evolution of metastatic hormone sensitive prostate cancer

6. Corrigendum to '589P Dynamics of peripheral blood immune profiling associated with tumour progression in metastatic castration resistant prostate cancer (mCRPC)'

7. 752P Updated data from the NORSE trial of erdafitinib (ERDA) plus cetrelimab (CET) in patients (pts) with metastatic or locally advanced urothelial carcinoma (mUC) and specific fibroblast growth factor receptor (FGFR) alterations

8. 759P Towards personalized medicine in MIBC: Immunohistochemistry-based taxonomical classification and outcome in patients treated with adjuvant chemotherapy

9. 662P Pembrolizumab (pembro) monotherapy as first-line therapy in advanced non–clear cell renal cell carcinoma (nccRCC): Results after a minimum of 34 months of follow-up from KEYNOTE-427 cohort B

10. 752P Updated data from the NORSE trial of erdafitinib (ERDA) plus cetrelimab (CET) in patients (pts) with metastatic or locally advanced urothelial carcinoma (mUC) and specific fibroblast growth factor receptor (FGFR) alterations

11. LBA27 Phase II multicenter, randomized study to evaluate efficacy and safety of avelumab with gemcitabine/carboplatin (CG) vs CG alone in patients with unresectable or metastatic urothelial carcinoma (mUC) who are ineligible to receive cisplatin-based therapy

12. 745P Patient-reported outcomes (PROs) from JAVELIN Bladder 100: Avelumab first-line (1L) maintenance + best supportive care (BSC) vs BSC alone for advanced urothelial carcinoma (UC)

13. 803TiP Pilot study of cabozantinib efficacy, safety and tolerability in metastatic renal carcinoma in aged fragile patients

14. 759P Towards personalized medicine in MIBC: Immunohistochemistry-based taxonomical classification and outcome in patients treated with adjuvant chemotherapy

15. PROSTRATEGY: A Spanish Genitourinary Oncology Group (SOGUG) multi-arm multistage (MAMS) phase III trial of immunotherapy strategies in high-volume metastatic hormone-sensitive prostate cancer

16. Durability related transport properties of OPC and slag cement mortars hardened under different environmental conditions

17. Long term prognosis of juvenile absence epilepsy

18. Differential gene expression profiles in poor vs good responders to maintenance vinflunine in patients (p) with advanced urothelial carcinoma (aUC): Preliminary results of biomarker analyses from the MAJA trial (SOGUG 2011/02)

19. Preliminary safety results of the randomized phase II ABIDO-SOGUG trial: Toxicity profile of concomitant abiraterone acetate + docetaxel treatment in comparison to docetaxel

20. Electrochemical extraction of chlorides from reinforced concrete using a conductive cement paste as the anode

21. Microstructural modifications in Portland cement concrete due to forced ionic migration tests. Study by impedance spectroscopy

22. Generalization of the possibility of eliminating the filtration step in the determination of acid-soluble chloride content in cement and concrete by potentiometric titration

23. A test method for measuring chloride diffusion coefficients through nonsaturated concrete

24. Longer time from diagnosis to docetaxel treatment results in a shorter survival in metastatic hormonosensitive prostate cancer (mHSPC) patients treated with chemotherapy+androgen deprivation therapy (ADT)

25. SPAZO2 (SOGUG): Comparative effectiveness of pazopanib in metastatic renal carcinoma (mRC): Ineligible (I) vs eligible (E) patients for clinical trials

26. Analysis of acid-soluble chloride in cement, mortar, and concrete by potentiometric titration without filtration steps

27. 2635 MAJA trial: maintenance vinflunine post cisplatin chemotherapy (CT) in patients with advanced urothelial carcinoma (UC). Preliminary analysis of a randomized placebo controlled phase II trial. SOGUG 2011-02. EudraCT 2011-001271-39

28. Chloride Contamination of Concrete by Interaction with PVC Combustion Gases

29. Proof by UV-visible modulated reflectance spectroscopy of the breakdown by carbonation of the passivating layer on iron in alkaline solution

30. 2635 MAJA trial: maintenance vinflunine post cisplatin chemotherapy (CT) in patients with advanced urothelial carcinoma (UC). Preliminary analysis of a randomized placebo controlled phase II trial. SOGUG 2011-02. EudraCT 2011-001271-39

31. Determination of the selectivity coefficient of a chloride ion selective electrode in alkaline media simulating the cement paste pore solution

32. A test method for measuring chloride diffusion coefficients through partially saturated concrete. Part II: The instantaneous plane source diffusion case with chloride binding consideration

33. 97 EVEROLIMUS (EVE) IN RECORD-1 ELDERLY PATIENTS (PTS) WITH METASTATIC RENAL CELL CARCINOMA (MRCC) AND MANAGEMENT OF RELATED ADVERSE EVENTS (AES)

34. Results of a phase II study of liposomal doxorubicin (Myocet®) in combination with weekly paclitaxel and trastuzumab (Herceptin®) In patients with HER2-positive locally advanced or metastatic breast cancer (LA/MBC)

35. A phase II study of vinorelbine (VRL), cisplatin (CDDP) and 5-Fluorouracil (FU) in patients (PTS) with locally advanced recurrent, and/or metastatic squamous cell carcinoma of the head and neck (SCCHN)

Catalog

Books, media, physical & digital resources